NS5A: A new target for antiviral drugs in the treatment of hepatitis C virus infection

被引：6
作者：
Debes, Jose D. [1 ]
Smith, Coleman I. [1 ]
机构：
[1] Univ Minnesota, Plymouth, MN USA
来源：
HEPATOLOGY | 2012年 / 56卷 / 03期
关键词：
GENOTYPE; 1; PROTEIN; REPLICATION; INHIBITOR; BMS-790052;
D O I：
10.1002/hep.25696
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：797 / 799
页数：3
相关论文
共 50 条
  • [1] A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir
    Fernandes Campos, Guilherme Rodrigues
    Ward, Joseph
    Chen, Shucheng
    Bittar, Cintia
    Vilela Rodrigues, Joao Paulo
    Candolo Martinelli, Ana de Lourdes
    Souza, Fernanda Fernandes
    Leira Pereira, Leonardo Regis
    Rahal, Paula
    Harris, Mark
    JOURNAL OF GENERAL VIROLOGY, 2021, 102 (01)
  • [2] In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A
    Asante-Appiah, Ernest
    Liu, Rong
    Curry, Stephanie
    McMonagle, Patricia
    Agrawal, Sony
    Carr, Donna
    Rokosz, Laura
    Lahser, Frederick
    Bystol, Karin
    Chase, Robert
    Black, Stuart
    Ferrari, Eric
    Ingravallo, Paul
    Tong, Ling
    Yu, Wensheng
    Kozlowski, Joseph
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (11)
  • [3] Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach
    Liu, Dandan
    Ji, Juan
    Ndongwe, Tanya P.
    Michailidis, Eleftherios
    Rice, Charles M.
    Ralston, Robert
    Sarafianos, Stefan G.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (06) : 3482 - 3492
  • [4] In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir
    Cheng, Guofeng
    Tian, Yang
    Doehle, Brian
    Peng, Betty
    Corsa, Amoreena
    Lee, Yu-Jen
    Gong, Ruoyu
    Yu, Mei
    Han, Bin
    Xu, Simin
    Dvory-Sobol, Hadas
    Perron, Michel
    Xu, Yili
    Mo, Hongmei
    Pagratis, Nikos
    Link, John O.
    Delaney, William
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (03) : 1847 - 1853
  • [5] Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir
    Komatsu, Takashi E.
    Boyd, Sarita
    Sherwat, Adam
    Tracy, LaRee
    Naeger, Lisa K.
    O'Rear, Julian J.
    Harrington, Patrick R.
    GASTROENTEROLOGY, 2017, 152 (03) : 586 - 597
  • [6] Potent Hepatitis C Virus NS5A Inhibitors Containing a Benzidine Core
    Bae, Il Hak
    Choi, Jin Kyu
    Chough, Chieyeon
    Keum, Sun Ju
    Kim, Heesun
    Jang, Sung Key
    Kim, B. Moon
    ACS MEDICINAL CHEMISTRY LETTERS, 2014, 5 (03): : 255 - 258
  • [7] Over-expression and characterization of NS3 and NS5A of Hepatitis C virus genotype 3a
    Anwar, Muhammad Ikram
    Iqbal, Mazhar
    Yousef, Mohammad S.
    Rahman, Moazur
    MICROBIAL CELL FACTORIES, 2013, 12
  • [8] NS5A resistance - associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey
    Sayan, Murat
    Yildirim, Figen Sarigul
    Akhan, Sila
    Yildirim, Arzu Altuncekic
    Sirin, Goktug
    Cabalak, Mehmet
    Demir, Mehmet
    Can, Selver
    Ersoz, Gulden
    Altintas, Engin
    Ensaroglu, Fatih
    Akbulut, Ayhan
    Sener, Alper
    Deveci, Aydin
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 95 : 84 - 89
  • [9] Odalasvir Nonstructural protein 5A (NS5A) inhibitor Treatment of hepatitis C virus (HCV)
    Kanda, T.
    Moriyama, M.
    DRUGS OF THE FUTURE, 2017, 42 (09) : 549 - 553
  • [10] Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents
    Nitta, Sayuri
    Asahina, Yasuhiro
    Matsuda, Mami
    Yamada, Norie
    Sugiyama, Ryuichi
    Masaki, Takahiro
    Suzuki, Ryosuke
    Kato, Nobuyuki
    Watanabe, Mamoru
    Wakita, Takaji
    Kato, Takanobu
    SCIENTIFIC REPORTS, 2016, 6
12345